Therapeutic Protein and Oral Vaccine Market

Global Therapeutic Protein and Oral Vaccine Market Size (2023 to 2028)

The worldwide therapeutic protein and oral vaccine market is anticipated to grow at a CAGR of 6.8% throughout the forecast period.

Global Therapeutic Protein and Oral Vaccine Market Share Insights:

• Based on product, the oral vaccines segment dominated the market in 2022.
• Based on the distribution channel, the online pharmacies segment held the largest share of the worldwide market in 2022.
• Based on application, the oncology segment accounted for the leading share of the global market in 2022.
• Based on region, North America captured the largest share of the global market in 2022.

Impact of COVID-19 on the therapeutic protein and oral vaccine market:

The COVID-19 pandemic crisis had positively impacted the therapeutic protein and oral vaccine market and has financially strengthened. The COVID-19 pandemic situation creates an emerging need for effective vaccines that leads to an accelerated focus on vaccine development. But due to certain restrictions on travel, social isolation and lockdown during the COVID-19 pandemic faced a disruption in clinical trials for COVID-19 therapeutic protein and oral vaccines. The COVID-19 pandemic situation has disrupted the global supply chain which hampers the manufacturing and distribution of therapeutic protein and oral vaccine market. The pandemic crisis also helps in the advancement of vaccine development technologies and methodologies. These advancements include mRNA-based vaccines, which potentially have broader implications for the development of therapeutic protein and oral vaccines. Thus, there was an increase in the demand for therapeutic protein and oral vaccine market.

MARKET DRIVERS: 

The growing prevalence of chronic diseases is one of the major factors propelling the growth of the global therapeutic protein and oral vaccine market. In a report published by CDS in 2022, it was revealed that more than 135 million adults had been diagnosed with diabetes and prediabetes. Thus, the symptom associated with diabetes and cancer demand the appropriate therapies and vaccination. Oral vaccines are more pertinent in the avoidance and control of chronic infectious diseases. The growing prevalence of those diseases is fueling the demand for oral vaccines and is driving the invention of novel therapeutic proteins that target specific disease pathways and offer improved options for therapy for the patients.

The growing need for therapeutic proteins and oral vaccines and rising prevalence of various illnesses, such as viral infections, autoimmune disorders and genetic disorders contributes to the global market growth. Factors such as the growing population worldwide and rapid adoption of sedentary lifestyles accelerating the demand for therapeutic protein and oral vaccines. Innovations in biotechnology, genetic engineering, recombinant technology, and drug delivery systems support the market growth.

The growing incidence of cancer promotes the growth of the therapeutic protein and oral vaccine market. In 2022, there were 2.1 million cases of cancer diagnosed with the treatment. To treat and manage cancer, therapeutic proteins and oral vaccines are needed. Because chemotherapy has numerous adverse reactions, treatment options such as therapeutic proteins and oral vaccines are being used instead. As a result, the rising prevalence of cancer has a direct impact on the therapies available. The rising incidence of cancer needs appropriate treatment and therapies and there is an increase in the demand for vaccination in case of cancer.

Factors such as favorable regulatory environment, technological advancements, growing healthcare expenditure, increasing research and development activities, public health initiatives and increasing vaccination programs further drive the growth of the therapeutic protein and oral vaccine market.

MARKET RESTRAINTS:

Factors such as high costs, stringent regulatory scenario and lower availability and affordability of therapeutic protein in lower-income countries hinder the growth rate of the worldwide market. The stringent regulatory condition including current good manufacturing practices, regulations, and recommendation state hampers the market growth. The need for regulatory conditions is crucial for enhancing product quality, efficacy, and safety; nevertheless, these processes are difficult and time-consuming, which hinders market expansion. Due to restricted manufacturing capacity as well as elevated manufacturing expenses, some therapeutic proteins also face issues with accessibility and affordability. This factor also hinders the market's expansion because it results in a limited supply and higher pricing for therapeutic proteins. The complexity of the manufacturing process raises production costs and makes it difficult to scale up production to meet demand, which is projected to have a negative impact on market growth.

REPORT COVERAGE: 

This research report on global therapeutic vaccine and oral vaccine market has been segmented and sub-segmented based on the following categories.

Therapeutic Protein and Oral Vaccine Market – By Product:

• Therapeutic Protein
• Oral Vaccine

Based on product, the oral vaccines segment is expected to showcase the domination in the global market during the forecast period owing to the growing awareness of consumers, rising preference for a sustainable and eco-friendly product and usage of cutting-edge technologies such as artificial intelligence and machine learning in vaccine productions.

On the other hand, the therapeutic protein segment is expected to witness the fastest CAGR in the worldwide market in the coming years owing to the technological advancements for protein-based drug development.

Therapeutic Protein and Oral Vaccine Market – By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel, the online pharmacies segment is expected to hold the leading share of the worldwide market during the forecast period. The COVID-19 pandemic situation has strengthened the digital commerce platform and resulted in the rapid growth of online pharmacies, which is driving the online pharmacies segmental growth in the global market primarily.

The hospital pharmacies segment is anticipated to showcase a promising CAGR in the worldwide market in the coming years.

Therapeutic Protein and Oral Vaccine Market – By Application:

• Oncology
• Hematology
• Immunology
• Endocrinology
• Infectious Diseases
• Cardiovascular Diseases

Based on application, the oncology segment is expected to dominate and register the highest CAGR during the forecast period. The growing use of therapeutic proteins and oral vaccines in cancer treatment, increasing demand for targeted and personalized therapies, growing cancer patient population, the development of monoclonal antibodies and other protein-based therapies for cancer and advances in immunotherapy and the potential of oral vaccines to enhance cancer immunity majorly drive the growth of the oncology segment in the global market.

The infectious diseases segment is anticipated to account for a considerable share of the global market during the forecast period owing to the ongoing threats from emerging infectious diseases and epidemics. Advances in vaccine development and protein-based antiviral/bacterial therapies and initiatives and funding from the governments of various countries to address infectious disease outbreaks further propel the growth of the infectious diseases segment.

Therapeutic Protein and Oral Vaccine Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America held the largest share of the global market in 2022 and the domination of the North American region in the global market is anticipated to continue throughout the forecast period. Factors such as the presence of leading pharmaceutical and biotech companies that conduct protein and vaccine research, strong regulatory frameworks supporting protein therapeutics and vaccines, high prevalence of chronic diseases and access to advanced healthcare majorly drive the market growth in North America. The U.S. followed by Canada are expected to account for the major share of the worldwide market in the coming years. The availability of robust healthcare infrastructure, high research and development investments, extensive biotechnology industry presence and continuous investments in innovative treatments propel the growth of the U.S. market.

Europe captured the second largest share of the global market in 2022 and is predicted to showcase a prominent CAGR in the coming years. Factors such as the growing biopharmaceutical industry engaged in protein and vaccine development, rising emphasis on public health and vaccination programs across European countries and growing demand for personalized and targeted therapies in chronic conditions propel the growth of the European market. Germany followed by UK and France accounts for the major share of the European market.

APAC is predicted to register the fastest CAGR in the worldwide market during the forecast period. Factors such as the growing healthcare investments, increasing disease burden and efforts to enhance healthcare access, the expansion of immunization programs and adoption of oral vaccines and growing prevalence of chronic diseases that demand effective protein-based therapies drive the growth of the APAC market.

Latin America is estimated to account for a considerable share of the global market during the forecast period. The MEA market is forecasted to register a steady growth rate in the coming years.

KEY MARKET PLAYERS:

Abbott, Amgen, Biogen, Eli Lilly and Company, Roche, Johnson and Johnson, Merck, Novo Nordisk, Pfizer, Sanofi, Serum Institute of India, Emergent Bio solutions, TransAlgae, MigVax, Lumen Bioscience are some of the notable companies in the global therapeutic protein and oral vaccine market.